We apologize for the recent sold-out situation on Coxor. New batches have now been delivered and will soon be available in the pharmacies.
We apologize for the sold-out situation of Coxor on the Norwegian market for the moment. The demand has been much higher than we could anticipate. We are working heavily to supply the market with new batches and will update as soon as the situation is remedied.
Press meeting regarding the Coxor launch was held today in Oslo. It was arranged by our licensing partner for the Nordics (Evolan AB) and organized by their PR and marketing partner (The Arch). The meeting was a success with high interest fra TV, radio and newspapers. Googling Coxor will give you an impression of what is stated by the press, the authorities and KOLs (Asamedic cannot due to regulation provide direct links).
USPTO has approved the Coxor® patent. This means that Coxor® currently has approved patent in Australia, Europe, USA, India, Indonesia and Mexico, with the RoW in patent pending.
Article following the Coxor clinical trial was today submitted for peer review:
Atar et al, "Randomized, open-label, crossover trial assessing the pharmacokinetic profile of a novel oral aspirin solution"
Preliminary analysis from the Coxor clinical trial shows faster uptake of Coxor versus comparator. Work commences for publishing of the results.
India informs that they will grant Coxor patent. Significant milestone that the world's 2nd most populated country (1,38 billion people) approves, and follows Australia and EPO.
India informs that they will grant Coxor patent. Significant milestone that the world's 2nd most populated country (1,38 billion people) approves, and follows Australia and EPO.
Delayed due to Covid, Coxor finally receives formal marketing authorization for Coxor in Denmark.
Indonesia (population 273 million) issues Coxor patent.
The European Patent Body, EPO, issues patent for Coxor. This is the second continent to approve the Coxor patent (Australia approved earlier).
Asamedic launches new pages in accordance with the strategy of more public transparency after obtained marketing authorization.
Today Asamedic received the national marketing authorization for Norway from NOMA (SLV).
Ordinary General Assembly scheduled for April 15th 2021 at 15:00. Meeting invitations to share holders will follow by e-mail.
The Norwegian Regional Ethical committee approves planned clinical trial. Work commences at Convex.
The trial is not required for regulatory purposes, but completed to confirm how Coxor has faster onset of action.
Asamedic has received positive conclusion on DCP procedure. For all practical purposes this means that Coxor has been granted Marketing Authorization (30 day local phases in Norway and Denmark remains to have local texts etc approved).
Both SLV and DKMA has approved Coxor as product brand name (former Asacor)